Morgan Stanley’s Annovis Bio ANVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.8K Sell
5,733
-4,168
-42% -$11.4K ﹤0.01% 6877
2025
Q4
$34.3K Buy
9,901
+2,512
+34% +$7.55K ﹤0.01% 6543
2025
Q3
$15.3K Sell
7,389
-4,805
-39% -$12K ﹤0.01% 6769
2025
Q2
$26.5K Buy
12,194
+2,005
+20% +$3.96K ﹤0.01% 6561
2025
Q1
$15.3K Buy
10,189
+8,889
+684% +$27.2K ﹤0.01% 6657
2024
Q4
$6.54K Sell
1,300
-50
-4% -$362 ﹤0.01% 6935
2024
Q3
$10.9K Sell
1,350
-4,148
-75% -$38.9K ﹤0.01% 6695
2024
Q2
$31.7K Sell
5,498
-1,658
-23% -$13.4K ﹤0.01% 6320
2024
Q1
$85.2K Buy
7,156
+4,288
+150% +$46.8K ﹤0.01% 6053
2023
Q4
$53.6K Buy
2,868
+1,434
+100% +$12.7K ﹤0.01% 6358
2023
Q3
$13.6K Buy
1,434
+22
+2% +$272 ﹤0.01% 6609
2023
Q2
$20.2K Sell
1,412
-289
-17% -$4.09K ﹤0.01% 6569
2023
Q1
$26.2K Sell
1,701
-27,955
-94% -$451K ﹤0.01% 6529
2022
Q4
$398K Sell
29,656
-11,631
-28% -$145K ﹤0.01% 5355
2022
Q3
$566K Sell
41,287
-14,851
-26% -$195K ﹤0.01% 5208
2022
Q2
$636K Sell
56,138
-53,920
-49% -$589K ﹤0.01% 5294
2022
Q1
$1.47M Sell
110,058
-44,923
-29% -$649K ﹤0.01% 4731
2021
Q4
$2.72M Buy
154,981
+117,015
+308% +$3.02M ﹤0.01% 4326
2021
Q3
$1.21M Buy
37,966
+7,896
+26% +$454K ﹤0.01% 4922
2021
Q2
$2.57M Buy
+30,070
New +$1.39M ﹤0.01% 4442
2021
Q1
Sell
-14,286
Closed -$108K 7479
2020
Q4
$108K Hold
14,286
﹤0.01% 5876
2020
Q3
$69K Buy
+14,286
New +$76.5K ﹤0.01% 5588

Other funds holding ANVS

Morgan Stanley's ANVS Position: Q1 2026 in Review

Morgan Stanley reduced its Annovis Bio (ANVS) stake by 42% in Q1 2026, selling an estimated $11.4K and leaving 5,733 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6877.

Morgan Stanley first reported a position in ANVS in Q3 2020 and has held it in 22 quarters since. The position peaked at $2.72M in Q4 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Morgan Stanley held 5,733 shares of Annovis Bio worth $12.8K as of Q1 2026.
  • Morgan Stanley sold 4,168 Annovis Bio shares in Q1 2026, an estimated $11.4K.
  • Annovis Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6877 holding.
  • Morgan Stanley first reported a position in Annovis Bio in Q3 2020 and has held it in 22 quarters since.
  • Morgan Stanley's Annovis Bio position peaked at $2.72M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.